Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
3,026 total articles
Cabaletta Bio (CABA) is a clinical-stage autoimmune cell therapy name with improving momentum, elevated short interest (about 11 days to cover), and several upcoming clinical and regulatory milestones. With the stock reclaiming key moving averages and still far below its 52-week high, this is a tactically interesting long trade. The setup is not ab…
Tesla’s stock is consolidating near $435 after a mild pullback, with momentum still soft but not broken. The market is paying a steep price for future software-like economics, and the TAAS narrative is the clearest path to justify that valuation. This trade idea looks for a reclaim of near-term trend levels with a tight stop, aiming for a push back…
Western Alliance (WAL) is acting like a regional bank that has regained its footing: the stock is holding above rising intermediate-term averages, valuation is still modest at ~11x earnings, and sentiment remains cautious enough to fuel upside if the market keeps warming to financials. With shares pulling back to the high-$80s, I like this as an up…
Tractor Supply has quietly rebuilt upside momentum into earnings while fundamentals still read like a quality compounder: strong ROE (about 43%), solid ROA (about 10%), and manageable leverage (debt-to-equity ~0.69). At roughly $29B market cap and ~26.6x earnings, the stock isn’t cheap, but it looks reasonable if 2026 guidance supports accelerating…
Boeing just put up the kind of order headline bulls want, but the tape is reminding investors that execution and cash conversion matter more than trophies. BA is down from its 01/22/2026 52-week high even as sentiment improves, creating a tradable long setup if price can reclaim key moving averages. This is a mid-term (45 trading days) trade idea b…
Apple is trading near $261 with improving momentum and a valuation that looks easier to defend than it did a few weeks ago, even though the product technology narrative (especially around AI-led form factors) still feels more speculative than confirmed. This sets up a pragmatic mid-term long trade: buy strength above key moving averages, target a m…
Clover Health is trading at $2.33 with a roughly $1.2B market cap and an EV/Sales near 0.7, while short interest remains elevated and technicals are oversold-leaning. The setup looks like a classic “left-for-dead” healthcare name where a modest improvement in profitability expectations can re-rate the stock quickly. This trade idea targets a move b…
Arista Networks sits in the critical “picks and shovels” layer of AI buildouts: high-speed switching, routing, and software that keeps data centers from choking on bandwidth. The stock is extended but technically strong, with bullish momentum signals and a clear level to define risk. This trade idea leans long, targeting a push back toward the prio…
Fortinet has the profile of a “boring” cybersecurity compounder that tends to look most interesting when the tape is choppy and the narrative turns temporarily negative. The stock is down materially from its $114.82 52-week high and is now trading around $81.57, even as the company continues to generate meaningful free cash flow and maintains stron…
Credo Technology is a pure-play on high-speed connectivity inside AI data centers. After a sharp drawdown from its 52-week high, CRDO is now trading with a depressed RSI and below key moving averages, setting up a defined-risk dip-buy trade. The bull case leans on real operating momentum (including triple-digit revenue growth cited in recent covera…
Lemonade has been trading like a momentum stock, but the underlying story the market is buying is simpler: AI-driven distribution plus better loss performance, inching the model toward profitability. With shares near $90 after a sharp run to $99.90, LMND offers a defined-risk long setup using the rising 10-day/20-day trend as a line in the sand. Th…
REGENXBIO (RGNX) is a clinical-stage gene therapy name with a clear event-window setup: a key FDA decision on its Hunter syndrome program is approaching, and the stock is coiling below near-term technical levels. With a ~$701M market cap, negative EPS (-$3.51), and meaningful short interest (about 5.0M shares; ~7.3 days to cover), price action can …
Energy Transfer is quietly tightening its operating narrative around long-life, contracted natural gas capacity, and the market is starting to pay attention. With ET back near $18, a 52-week range of $14.60-$21.16, and bullish technical momentum, the trade setup is attractive if you respect the overbought signals. This is a mid-term (45 trading day…
Intel has sprinted off its 2025 lows and is now pulling back from a fresh 52-week high near $54.60. The tape looks like a classic digestion phase: RSI is neutral (~47.8), price is sitting near the 20-day average, and MACD is still barely positive. My trade idea is to go long on this reset, looking for a move back toward the mid-to-upper $50s as 202…
Nebius (NBIS) is acting like a classic AI infrastructure momentum name: headline-driven volatility on top of a simpler underlying engine - demand for GPU capacity. With shares back near a key support zone around the mid-$90s and short interest elevated, the risk-reward favors a defined long trade as long as $91 support holds. This is not a ‘sleep w…
Allstate is trading like underwriting is still fully at the mercy of the cycle. But the profitability profile implied by a 30% ROE and a single-digit P/E suggests a structurally improved earnings engine. With the stock sitting below key moving averages and momentum still bearish, this is a mid-term long idea that looks like it’s offering entry rath…
Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …
Spotify has pulled back sharply from its 52-week highs and is now sitting near short-term moving averages with an oversold RSI around 35. The tape still shows bearish momentum, but the dip is starting to look more like exhaustion than the start of a fresh breakdown. This trade idea is a defined-risk long that leans on mean reversion back toward the…
Alphabet has climbed back near its highs with a ~$4.02T market cap and a ~$335 share price, but the valuation is getting harder to justify if free cash flow doesn’t re-accelerate. At ~32x earnings and a rich ~55x free cash flow multiple, the market is paying up for an AI-driven upside scenario at the same time momentum is rolling over (bearish MACD…
Strattec Security (STRT) is an overlooked auto supplier trading at modest earnings and low sales multiples despite strong free cash flow generation, low leverage, and improving operational execution. With the stock consolidating below recent highs and valuation still reasonable, the setup favors a defined-risk long trade aimed at a retest of the 52…
Kroger has quietly tightened its narrative around core grocery, leaned into personalization through Google Cloud’s Gemini CX rollout, and backed shareholder returns with a new $2 billion repurchase authorization. With shares near $63.70, improving momentum signals, and a defensive demand profile, KR offers a pragmatic mid-term long setup: defined d…
ClearPoint Neuro sold off hard into $14 despite improving momentum signals and steady liquidity metrics. With the stock sitting near its 50-day average, short interest elevated, and the business positioned around MRI-guided minimally invasive neurosurgery platforms, the risk-reward favors a defined mid-term rebound trade back toward the mid-teens t…
Dyne Therapeutics sits at an interesting intersection for biotech traders: a beaten-down-to-basing chart near $18, meaningful short interest, and a 2026 narrative tied to progress in genetically driven muscle diseases. With liquidity that looks more like a well-funded developer than a fragile microcap, the risk can be framed with a clean stop while…
OPKO Health (OPK) sits in a weird place the market tends to misprice: a sub-$1.1B health services and biopharma hybrid with credible assets, real operating infrastructure, and a long history that has trained investors to shrug. At ~$1.30, the stock is priced like the future is mostly disappointment. But the setup says the opposite is plausible - va…
FLGT has rebounded enough that the stock no longer screams deep value, but valuation is still reasonable for a company with no debt, strong liquidity, and a chart that’s stabilizing. I like a defined-risk long trade into the $30-$31 area, with a tight stop under recent support.
